VBI Vaccines Q4 2022 Earnings Report

VBI Vaccines EPS Results

• Actual EPS: -$1.60
• Consensus EPS: -$1.40
• Beat/Miss: Missed by -$0.20
• One Year Ago EPS: N/A

VBI Vaccines Revenue Results

• Actual Revenue: $0.29 million
• Expected Revenue: $1.98 million
• Beat/Miss: Missed by -$1.69 million
• YoY Revenue Growth: N/A

VBI Vaccines Announcement Details

• Quarter: Q4 2022
• Date: 3/13/2023
• Time: Q4 2022 Earnings Release

VBI Vaccines (NASDAQ:VBIV), a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.